<DOC>
	<DOCNO>NCT03103321</DOCNO>
	<brief_summary>This randomized phase III trial study well decision aid work improve knowledge patient prostate cancer . Decision aid may improve patient ' knowledge condition option treatment , may also help talk doctor .</brief_summary>
	<brief_title>Decision Aids Improving Knowledge Patients With Prostate Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To test comparative effectiveness decision aid ( DA 's ) patient knowledge . SECONDARY OBJECTIVES : I . To test impact in-visit DA 's alone compare usual care quality life outcomes treatment utilization . II . To test impact out-of-visit DA 's alone compare usual care quality life outcomes treatment utilization . III . To test impact combine in-visit out-of-visit DA 's compare usual care individual DAs quality life outcomes treatment utilization . IV . To test comparative effectiveness DA 's minority men 's knowledge . V. To compare clinic time require administer DA 's across arm . OUTLINE : Patients randomize 1 4 arm . ARM A : Patients receive decision aid `` Knowing Options '' `` Prostate Choice '' consultation visit . ARM B : Patients receive `` Knowing Options '' decision aid consultation visit . ARM C : Patients receive `` Prostate Choice '' decision aid consultation visit . ARM D : Patients undergo usual care . After completion study , patient follow 12 month .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Patients must prostate biopsy within 4 month prior registration show newly diagnose prostate cancer , stage T13N0M0 ; addition , patient must : Gleason score 610 Prostatespecific antigen ( PSA ) &lt; 50 ng/mL Patients history noncutaneous malignancy previous 5 year eligible ; exception : patient history nonmelanoma skin cancer eligible Scheduled prostate cancer consultation first consultation diagnosis ( i.e . secondopinion consultation follow previous discussion treatment option ) Patients may concurrently enrol another clinical trial treatment cancer ; coenrollment biospecimen study allow Patients impaired decisionmaking capacity ( diagnosis dementia memory loss ) eligible study Patients must able read comprehend English ; nonEnglishspeaking patient may participate long interpreter ( e.g. , family member , clinic staff , etc . ) present consent , decision aid administration , gather baseline followup measure</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>